
AstraZeneca will buy Fusion Pharma for a price close to US$2.4 billion
AstraZeneca Plc has agreed to buy Fusion Pharmaceuticals Inc. for US$2.4 billion, at a time when European pharmaceutical companies continue their streak of agreements with promising biotechnology companies. The British drugmaker said it will pay $21 per share for Fusion, or $2 billion in cash upfront. plus another US$400 million depending on the milestones achieved. ...











